Drugs / B/F/TAF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03405935 | Mar → Nov 2018 | HIV infectious disease | Gilead Sciences | Completed | Met primary |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-10-15 | Gilead Sciences | Results Gilead Presents New HIV Research Data at EACS 2025 – Driving Scientific Innovation in Treatment and Prevention gilead.com ↗
The investigational combination has the potential to be the first twice-yearly complete regimen. |
| 2020-10-21 | Gilead Sciences | Results Gilead Announces New Data on Biktarvy® for the Treatment of HIV in Black Americans gilead.com ↗
After one year, those who switched from TDF to TAF (n=828) and those who switched from abacavir (ABC) to TAF (n=142) experienced a mean unadjusted weight gain of 1.4 kg and 0.2 kg, respectively (p=0.039). |
| 2020-07-04 | Gilead Sciences | Results New Findings on Gilead’s Biktarvy® Presented at AIDS 2020: Virtual Include Positive Switch Data in Older Adults gilead.com ↗
Viral blips were infrequent and similar among study participants switching to Biktarvy or DTG+F/TAF, and baseline NRTI resistance did not result in a higher rate of blips. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-10-15 | Gilead Sciences | Gilead Presents New HIV Research Data at EACS 2025 – Driving Scientific Innovation in Treatment and Prevention gilead.com ↗ |
| 2020-10-21 | Gilead Sciences | Gilead Announces New Data on Biktarvy® for the Treatment of HIV in Black Americans gilead.com ↗ |
| 2020-07-04 | Gilead Sciences | New Findings on Gilead’s Biktarvy® Presented at AIDS 2020: Virtual Include Positive Switch Data in Older Adults gilead.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | B/F/TAF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03405935 ↗ |
| Known as | Bictegravir/emtricitabine/tenofovir alafenamide | “Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is an effective treatment for HIV-1 infection; however, clinical trial data in older people living with HIV (PLWH) are lacking.” PMID 35527425 ↗ May 2022 |
| Route | Oral | “administered orally” NCT03405935 ↗ |